Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, raised the proposed deal size for its upcoming IPO on Wednesday. The Boston, MA-based company now plans to raise $283 million by offering 16.7 million shares at a...read more
Pershing Square USA, a closed-end investment vehicle formed by Bill Ackman, raised $5 billion by selling shares at $50 per share. The company raised $2.2 billion by selling 44 million shares in a registered offering to public investors, as well as $2.8 billion...read more
Join Renaissance's director of investment strategies for the Weekly Weigh-in. In this edition, Avery discusses how to interpret Kraken's recent valuation cut. To stay on top of the IPO market, make sure to sign up for our weekly newsletter.
Pulmonary fibrosis biotech Avalyn Pharma increases shares offered by 41% ahead of $283 million IPO
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, raised the proposed deal size for its upcoming IPO on Wednesday. The Boston, MA-based company now plans to raise $283 million by offering 16.7 million shares at a...read more
Bill Ackman's closed-end fund Pershing Square USA prices $5 billion IPO at $50 per share; manager Pershing Square Inc. also set to trade on the NYSE
Pershing Square USA, a closed-end investment vehicle formed by Bill Ackman, raised $5 billion by selling shares at $50 per share. The company raised $2.2 billion by selling 44 million shares in a registered offering to public investors, as well as $2.8 billion...read more
IPO Weekly Weigh-in: Kraken’s pre-IPO haircut?
Join Renaissance's director of investment strategies for the Weekly Weigh-in. In this edition, Avery discusses how to interpret Kraken's recent valuation cut. To stay on top of the IPO market, make sure to sign up for our weekly newsletter.
...read more